Musculoskeletal Disorders Drugs Market Expected to Reach $126 Billion by 2032—Allied Market Research

According to a new report published by Allied Market Research, titled, “Musculoskeletal Disorders Drugs Market," The musculoskeletal disorders drugs market size was valued at $83.5 billion in 2022, and is estimated to reach $126 billion by 2032, growing at a CAGR of 4.2% from 2023 to 2032. The musculoskeletal disorders drugs market analysis from 2022 to 2032 to identify the prevailing musculoskeletal disorders drugs market opportunity.

Rise in incidences and prevalence of musculoskeletal disorders such as rheumatoid arthritis, osteoporosis ankylosing spondylitis, increase in geriatric population as they are more prone to musculoskeletal disorders, and rise in pipeline drugs are the major drivers of this market. In addition, strong presence of promising pipeline drugs, presence of large patient pool, increase in adoption of novel treatments, and surge in R&D activities to develop new drugs for the treatment of musculoskeletal disorders are expected to boost the musculoskeletal disorders drugs market size growth during the forecast period.   

Furthermore, high growth in untapped countries are expected to offer lucrative opportunities for market expansion during the forecast period. However, lack of access to treatment for rheumatoid arthritis in underdeveloped countries which is expected to hamper the growth of musculoskeletal disorders drugs market share. The expansion of R&D, ongoing medicine approvals, and rapid growth potential in untapped countries, on the other hand are expected to provide numerous opportunities for market growth during the forecast period.   

Many patients with musculoskeletal disorders had reduced access to care due to the pandemic. This led to delays in diagnosis or treatment, which had negative impacts on patient outcomes. In addition, many of the orthopedic surgeries either canceled or postponed due to pandemic. Furthermore, wave of COVID-19 spread has create burden on hospitals, resulting in many surgeries postponed and had longer waiting time. For instance, according to report by British Broadcasting Corporation (BBC), due to second wave of COVID-19 around 4.7 million people were waiting for routine operations and procedures in England in Feb 2021.  This had significantly decline of the global musculoskeletal disorders drugs market share.  

Depending on drug type, the market is classified into analgesics, DMARDs, corticosteroids, and others. The analgesics segment exhibited largest share in 2022. This was attributed high effectiveness, ease of accessibility, and cost-effectiveness of analgesics make them a popular choice for managing pain and inflammation associated with musculoskeletal disorders. In addition, rise in number of clinical studies lead to introduction of novel products in market which further supports growth of the musculoskeletal disorders drugs market trends. 

Depending on route of administration, the market is categorized into oral, and parenteral. The parenteral segment exhibited largest share in 2022. This is attributed to rise in geriatric population along with rise in prevalence of rheumatoid arthritis, leading to an increase in the demand for injectable drugs that treat condition. In addition, injectable drugs are effective in the treatment of musculoskeletal disorders which is expected to fuel the segment growth. However, the oral segment exhibited the fastest CAGR growth during the musculoskeletal disorders drugs market forecast period. This is attributed to availability of wide variety of oral drugs, less expensive than other route drugs, and easy to administer.  

Depending on distribution channel, the musculoskeletal disorders drugs industry is segregated into hospital pharmacies, online providers, and drug store & retail pharmacies. The drug store & retail pharmacies segment dominated the market in 2022, owing to availability of medications such as analgesics in drug stores & retail pharmacies. However, the online providers segment exhibited the fastest CAGR growth during the forecast period. This is attributed to availability of a musculoskeletal drugs such as analgesics and disease modifying anti-rheumatic drugs (DMARDs) on e-commerce platforms which helps patients buy products at ease, and increased access to information offered by online providers make them an attractive option for patients with musculoskeletal disorders who require medications for their treatment.   

Region wise, North America was the largest shareholder in the global musculoskeletal disorders drugs market in 2022, owing to presence of large patient population, presence of major key players, ease of drug availability, high prevalence of musculoskeletal disease favorable reimbursement policies in healthcare system, and higher adoption of advanced therapeutics. In addition, the surge in the proportion of new drug launches and product approvals by the U.S. FDA is expected to drive the market growth in the region during the forecast period. For instance, in January 2022, AbbVie announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis (PsA), a systemic inflammatory disease that affects the skin and joints.   

However, Asia-Pacific is anticipated to register the highest CAGR during the forecast period, owing to rise in geriatric population with rise in health awareness, developing healthcare infrastructure, rise in prevalence of rheumatoid arthritis and surge in patient awareness toward the use of musculoskeletal disorders drugs.  

Key Findings of The Study

• By drug type, the analgesics segment held largest share in the global market in 2022.  

• By route of administration, the parenteral segment dominated the market in 2022. 

• By distribution channel, the drug stores & retail pharmacies segment dominated the market in 2022. 

• Region wise, North America generated the largest revenue in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.